

# Evolving treatment landscape in ER+ advanced breast cancer: clinical practice

Novartis would like to invite you to attend their sponsored symposium '**Evolving treatment landscape in ER+ advanced breast cancer: clinical practice**'. Join us to discover more about advances in treatment and the exciting use of PI3K inhibitors.

---

**Date:** Saturday 23<sup>rd</sup> November 2019

**Time:** 12:45–14:15 SGT

**Location:** Room 324, Level 3,  
Suntec Singapore Convention & Exhibition Centre,  
Singapore

---

## Satellite symposium agenda:

Time	Topic/Presenter
12:45	Introduction <i>Professor Yen-Shen Lu</i>
12:50	Achieving success when treating young patients with breast cancer <i>Professor Yen-Shen Lu</i>
13:10	Treatment paradigms in the era of CDK 4/6 inhibitors: an Asian perspective <i>Dr Yoon Sim Yap</i>
13:30	PI3K inhibitors in advanced breast cancer: what has changed? <i>Dr Barbara Pistilli</i>
13:50	Panel discussion <i>Professor Yen-Shen Lu, Dr Yoon Sim Yap, Dr Barbara Pistilli</i>
14:10	Conclusions <i>Professor Yen-Shen Lu</i>

**Reimagining medicine to transform cancer**

CDK, cyclin-dependent kinase; ER+, estrogen receptor-positive; PI3K, phosphoinositide 3-kinase.

Novartis has paid for the organisational cost of this meeting, and honoraria for the chairperson and speakers. Novartis has contributed to the content and agenda of this meeting.